NCT00863850View on ClinicalTrials.gov

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions

Malignancy

Interventions

DRUG

bendamustine

Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.

Trial Locations (1)

1066 CX

Please Call For Information, Amsterdam